(10-Phenylanthracen-9-yl)boronic acid | CAS:334658-75-2

We serve (10-Phenylanthracen-9-yl)boronic acid CAS:334658-75-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
(10-Phenylanthracen-9-yl)boronic acid

Chemical Name:(10-Phenylanthracen-9-yl)boronic acid
CAS.NO:334658-75-2
Synonyms:10-Phenyl-9-anthraceneboronic acid
10-phenylanthracen-9-ylboronic acid
9-Borono-10-phenylanthracene
10-Phenyl-9-anthracene boronic acid
Molecular Formula:C20H15BO2
Molecular Weight:298.14300
 
Physical and Chemical Properties:
Density:1.27
Boiling point:521.325ºC
Flash point:269.088ºC
Index of Refraction:1.727
 
Specification:
Appearance:White powder
Assay:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates



Contact us for information like (10-Phenylanthracen-9-yl)boronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,10-Phenyl-9-anthracene boronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(10-Phenylanthracen-9-yl)boronic acid Use and application,10-phenylanthracen-9-ylboronic acid technical grade,usp/ep/jp grade.


Related News: TSA notified airlines Saturday about the restrictions. CNN is reaching out to TSA for comment.3-(5-chloro-2-phenoxyphenyl)-1-methylpyrrolidine-2,4-dione manufacturer The US National Institutes of Health is working on a preventative vaccine, but it will likely take a few months until the first phase of clinical trials get underway, and more than a year until a vaccine might be available, according to experts.4-phenylbutan-1-ol supplier Therefore, the growth of the global pharmaceutical market has greatly affected the development of the entire intermediate and API industry.1-Methylazepan-4-one vendor Subsequently, the company launched the drug under the brand names ‘Remo’ and ‘Remozen’.Large pharmaceutical companies are investing a disproportionately large amount of annual revenue in research and development (R&D), according to GlobalData’s Company Financials database.